Glatiramer

Title: Glatiramer
CAS Registry Number: 28704-27-0
CAS Name: L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine
Additional Names: copolymer 1; COP 1 (polyamide); COP 1
Literature References: Random basic synthetic copolymer of L-alanine, L-lysine, L-glutamic acid and L-tyrosine in a molar ratio of 6:1.9:4.7:1. Mol wt of 14,000 to 23,000 Da. Immunologically cross reactive with myelin basic protein. Prepn: D. Teitelbaum et al., Eur. J. Immunol. 1, 242 (1971). Suppression of exptl. allergic encephalomyelitis (EAE): eidem, ibid. 3, 273 (1973). Inhibition of T-cell response to myelin basic protein: D. Teitelbaum et al., Proc. Natl. Acad. Sci. USA 89, 137 (1992); of binding to major histocompatibility complex: M. Fridkis-Hareli et al., ibid. 91, 4872 (1994). Clinical trials in multiple sclerosis: M. B. Bornstein et al., Neurology 41, 533 (1991); K. P. Johnson et al., ibid. 45, 1268 (1995). Review of pharmacology and early clinical evaluation: L. A. Rolak, Clin. Neuropharmacol. 10, 389 (1987); suppression of EAE: R. Arnon, Israel J. Med. Sci. 25, 686-689 (1989).
Derivative Type: Acetate
CAS Registry Number: 147245-92-9
Trademarks: Copaxone (Teva)
Therap-Cat: Immunomodulator; in treatment of multiple sclerosis.
Keywords: Immunomodulator.
Glaucarubin Glaucine Gliadin Glibornuride Gliclazide

Glatiramer acetate
Clinical data
AHFS/Drugs.com monograph
Licence data US FDA:link
Pregnancy cat. B (US)
Legal status -only (US)
Identifiers
CAS number 147245-92-9 YesY
ATC code L03AX13
PubChem CID 3081884
DrugBank DB05259
UNII 5M691HL4BO N
ChEMBL CHEMBL1201507 N
Chemical data
Formula C25H45N5O13 
Mol. mass 623.65 g/mol
 N (what is this?)  (verify)

Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone - as marketed by Teva Pharmaceuticals) is an immunomodulator drug currently used to treat multiple sclerosis. It is a random polymer of four amino acids found in myelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine, and may work as a decoy for the immune system. Glatiramer acetate is approved by the Food and Drug Administration (FDA) for reducing the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability.

Although the clinical definition of multiple sclerosis requires two or more episodes of symptoms and signs, glatiramer acetate is approved for treatment after single episodes. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.